Search Results
Search this site
658 results found with an empty search
- US Pathologist Compensation Reaches $410,039 in Doximity’s 2026 Report
Average annual compensation for US pathologists reached $410,039 in Doximity’s 2026 Physician Compensation Report, providing an updated national benchmark for physicians working in pathology. US pathologists recorded average annual compensation of $410,039, according to Doximity’s 2026 Physician Compensation Report. The latest figure provides pathologists with a specialty-specific benchmark when evaluating their compensation, employment opportunities and the financial expectations associated with their practice. Key findings Doximity reports average annual compensation of $410,039 for pathologists in its 2026 Physician Compensation Report. For pathologists, the figure provides a useful national reference point within a specialty central to disease diagnosis, laboratory medicine and the interpretation of tissue, cellular and molecular findings. The national average should not be interpreted as the compensation every pathologist will receive. Individual earnings can vary according to geography, experience, subspecialty expertise, workload, practice setting and employment structure. Pathologist compensation reaches $410,039 The $410,039 average establishes a current national compensation benchmark for US pathologists. Pathology encompasses a broad range of diagnostic activity, including the examination of tissue and cellular samples, laboratory medicine and the interpretation of tests used to diagnose and characterise disease. Individual pathologists may develop expertise in areas such as surgical pathology, hematopathology, cytopathology, molecular pathology, dermatopathology, neuropathology or forensic pathology. The nature of the workload can therefore vary substantially depending on subspecialty, specimen volumes, case complexity and the clinical services supported by the laboratory. For pathologists reviewing their current compensation or considering a new position, the Doximity figure provides a useful specialty-specific reference against which an individual package can be assessed. What influences pathologist compensation? Pathology is a diagnostically intensive specialty, meaning case volume, diagnostic complexity, subspecialty expertise and practice structure can all be important when evaluating individual compensation. A pathologist working predominantly in high-volume surgical pathology may have a substantially different workload from one specialising in molecular diagnostics, hematopathology or another highly specialised area. The increasing role of biomarker and molecular testing in areas such as oncology can also add complexity to diagnostic workflows, requiring integration of histopathological findings with molecular and genomic information. Practice setting can further influence compensation. Pathologists may work within hospitals, academic medical centres, health systems, independent laboratories or specialist pathology groups, with different organisations using different salary, productivity and incentive arrangements. These factors mean the $410,039 national average should be treated as a benchmark rather than an expected salary for every pathologist. What the latest figure means for pathologists For US pathologists, $410,039 provides a contemporary national reference point when benchmarking existing compensation or assessing a prospective position. When reviewing an employment opportunity, pathologists should consider headline compensation alongside expected case volumes, diagnostic complexity, subspecialty responsibilities, working hours and productivity requirements. Subspecialty expertise is particularly relevant. The responsibilities associated with hematopathology, molecular pathology or complex oncologic diagnostics, for example, can differ substantially from those of a broader general pathology role. The latest Doximity figure therefore provides pathologists with a useful starting point for evaluating compensation while recognising that individual earnings can differ substantially according to the diagnostic workload, specialist expertise and contractual characteristics of a particular role. About the data The Doximity 2026 Physician Compensation Report provides compensation benchmarks across a wide range of US medical and surgical specialties. The specialty figures represent average compensation and should be treated as national benchmarks. An individual pathologist’s compensation may differ according to geography, experience, subspecialty, diagnostic workload, practice setting and other professional factors. Source Doximity. Physician Compensation Report 2026.https://www.doximity.com/reports/physician-compensation-report/2026#modal-close Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- US Ob/Gyn Compensation Reaches $420,859 in Doximity’s 2026 Report
Average annual compensation for US obstetricians and gynecologists reached $420,859 in Doximity’s 2026 Physician Compensation Report, providing an updated national benchmark for physicians working in Ob/Gyn. US obstetricians and gynecologists recorded average annual compensation of $420,859, according to Doximity’s 2026 Physician Compensation Report. The latest figure provides Ob/Gyn physicians with a specialty-specific benchmark when evaluating their compensation, employment opportunities and the financial expectations associated with their practice. Key findings Doximity reports average annual compensation of $420,859 for Obstetrics & Gynecology physicians in its 2026 Physician Compensation Report. For Ob/Gyn physicians, the figure provides a useful national reference point within a specialty combining longitudinal women's healthcare with pregnancy and childbirth management, diagnostic procedures and surgery. The national average should not be interpreted as the compensation every Ob/Gyn physician will receive. Individual earnings can vary according to geography, experience, patient volume, surgical and obstetric workload, call responsibilities, practice setting and employment structure. Ob/Gyn compensation reaches $420,859 The $420,859 average establishes a current national compensation benchmark for US obstetricians and gynecologists. Ob/Gyn encompasses care across a broad range of women's health needs, including pregnancy, childbirth, reproductive health, gynecological conditions and preventive care. Clinical practice can combine outpatient consultations and longitudinal patient management with deliveries, diagnostic procedures and gynecological surgery. The balance between obstetric and gynecological work can therefore create substantially different workloads between individual physicians. Ob/Gyn physicians may also develop additional expertise in areas such as maternal-fetal medicine, reproductive endocrinology and infertility, gynecologic oncology or female pelvic medicine and reconstructive surgery. For Ob/Gyn physicians reviewing their current compensation or considering a new position, the Doximity figure provides a useful specialty-specific reference against which an individual package can be assessed. What influences Ob/Gyn compensation? Ob/Gyn combines outpatient medicine with significant obstetric, procedural and surgical responsibilities, meaning patient volume, delivery workload, procedure mix and call commitments can all be important when evaluating individual compensation. Obstetric responsibilities can have a particularly significant impact on working patterns. Physicians providing maternity services may need to cover deliveries and urgent obstetric care outside conventional working hours, including nights and weekends. The balance of obstetrics and gynecology can also affect the demands of a role. A physician with a substantial delivery workload may have a different practice profile from one concentrating more heavily on outpatient gynecology and surgery. Geography, experience and employment model may further influence compensation. Ob/Gyn physicians can work within hospitals, health systems, academic medical centres, specialist groups and independent practices, with different organisations using different salary, productivity and incentive arrangements. These factors mean the $420,859 national average should be treated as a benchmark rather than an expected salary for every Ob/Gyn physician. What the latest figure means for Ob/Gyn physicians For US obstetricians and gynecologists, $420,859 provides a contemporary national reference point when benchmarking existing compensation or assessing a prospective position. When reviewing an employment opportunity, Ob/Gyn physicians should consider headline compensation alongside expected patient volumes, delivery numbers, surgical responsibilities, call frequency, working hours and productivity requirements. The balance between obstetric and gynecological responsibilities is particularly important. Two Ob/Gyn positions can involve substantially different workloads depending on maternity coverage, operative activity, outpatient responsibilities and the availability of specialist clinical support. The latest Doximity figure therefore provides Ob/Gyn physicians with a useful starting point for evaluating compensation while recognising that individual earnings can differ substantially according to the clinical and contractual characteristics of a particular role. About the data The Doximity 2026 Physician Compensation Report provides compensation benchmarks across a wide range of US medical and surgical specialties. The specialty figures represent average compensation and should be treated as national benchmarks. An individual Ob/Gyn physician’s compensation may differ according to geography, experience, patient volume, obstetric and surgical workload, call responsibilities, practice setting and other professional factors. Source Doximity. Physician Compensation Report 2026.https://www.doximity.com/reports/physician-compensation-report/2026#modal-close Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- US Emergency Medicine Physician Compensation Reaches $423,723 in Doximity’s 2026 Report
Average annual compensation for US emergency medicine physicians reached $423,723 in Doximity’s 2026 Physician Compensation Report, providing an updated national benchmark for physicians working in emergency medicine. US emergency medicine physicians recorded average annual compensation of $423,723, according to Doximity’s 2026 Physician Compensation Report. The latest figure provides emergency physicians with a specialty-specific benchmark when evaluating their compensation, employment opportunities and the financial expectations associated with their practice. Key findings Doximity reports average annual compensation of $423,723 for emergency medicine physicians in its 2026 Physician Compensation Report. For emergency physicians, the figure provides a useful national reference point within a specialty characterised by acute and unscheduled care, rapid clinical decision-making and the management of patients across a broad spectrum of medical and surgical emergencies. The national average should not be interpreted as the compensation every emergency medicine physician will receive. Individual earnings can vary according to geography, experience, shift patterns, clinical workload, practice setting and employment structure. Emergency medicine physician compensation reaches $423,723 The $423,723 average establishes a current national compensation benchmark for US emergency medicine physicians. Emergency medicine encompasses the assessment, stabilisation and treatment of patients presenting with acute illness and injury. Physicians may manage everything from cardiovascular and neurological emergencies to trauma, respiratory illness, infections and other urgent conditions during a single shift. Unlike many outpatient specialties, emergency medicine operates around continuous hospital coverage. Evening, overnight, weekend and holiday shifts can therefore form a significant part of an emergency physician's working pattern. For emergency medicine physicians reviewing their current compensation or considering a new position, the Doximity figure provides a useful specialty-specific reference against which an individual package can be assessed. What influences emergency medicine physician compensation? Emergency medicine has a distinctive working model, meaning shift patterns, clinical workload, patient acuity and practice location can all be important when evaluating individual compensation. The demands of an individual role can differ substantially depending on emergency department volume, patient complexity, trauma designation and the availability of specialist and clinical support. Working patterns are also particularly relevant. Compensation arrangements may need to reflect evening, overnight, weekend and holiday coverage as well as the number and length of shifts undertaken. Geography and employment structure can further influence compensation. Emergency physicians may work directly for hospitals and health systems or through physician groups and other staffing models, with different organisations using different hourly, shift-based, productivity or salaried compensation arrangements. These factors mean the $423,723 national average should be treated as a benchmark rather than an expected salary for every emergency medicine physician. What the latest figure means for emergency medicine physicians For US emergency medicine physicians, $423,723 provides a contemporary national reference point when benchmarking existing compensation or assessing a prospective position. When reviewing an employment opportunity, emergency physicians should consider headline compensation alongside the number of annual clinical hours, shift length, overnight and weekend requirements, patient volumes, acuity and productivity expectations. The clinical environment is particularly important in emergency medicine. Two positions can carry substantially different demands depending on whether a physician is working in a high-volume urban emergency department, trauma centre, community hospital or another emergency care setting. The latest Doximity figure therefore provides emergency medicine physicians with a useful starting point for evaluating compensation while recognising that individual earnings can differ substantially according to the workload, schedule and contractual characteristics of a particular role. About the data The Doximity 2026 Physician Compensation Report provides compensation benchmarks across a wide range of US medical and surgical specialties. The specialty figures represent average compensation and should be treated as national benchmarks. An individual emergency medicine physician’s compensation may differ according to geography, experience, clinical workload, shift pattern, practice setting and other professional factors. Source Doximity. Physician Compensation Report 2026.https://www.doximity.com/reports/physician-compensation-report/2026#modal-close Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- Novartis' Phase III pelacarsen trial misses primary cardiovascular endpoint
Novartis reports that the Phase III Lp(a)HORIZON study of pelacarsen did not meet its primary cardiovascular endpoint in patients with elevated lipoprotein(a) and established cardiovascular disease. The Phase III Lp(a)HORIZON trial did not demonstrate a statistically significant reduction in major adverse cardiovascular events with pelacarsen compared with placebo, despite substantially lowering lipoprotein(a) levels. Novartis said it will analyse the full dataset to better understand the findings, with the result carrying implications for the emerging field of Lp(a)-targeted cardiovascular therapies. Field Content Alert Type Phase III clinical trial results Company Novartis Drug / Asset Pelacarsen Trial Lp(a)HORIZON Development Stage Phase III Therapy Area(s) Cardiovascular disease Target Lipoprotein(a) [Lp(a)] Patient Population Patients with elevated Lp(a) and established cardiovascular disease What Happened The Phase III Lp(a)HORIZON study did not meet its primary endpoint, with pelacarsen failing to demonstrate a statistically significant reduction in major adverse cardiovascular events compared with placebo. Why It Matters The result is significant for Novartis and the wider development of therapies targeting elevated Lp(a), an important genetically determined cardiovascular risk factor. Supporting Context Pelacarsen substantially lowered Lp(a) levels in the study, but this did not translate into a statistically significant reduction in the trial's primary cardiovascular endpoint. Key Takeaway Lp(a)HORIZON missed its primary cardiovascular endpoint despite the expected reduction in Lp(a), leaving further analysis of the trial data important for understanding the future role of pelacarsen. What to Watch Novartis' further analysis and presentation of the complete Lp(a)HORIZON dataset, including secondary endpoints and subgroup findings. Primary Source Novartis Relevant Date 4 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- Novartis India targets therapy-aligned acquisitions and expansion into Tier 2 and Tier 3 markets
Novartis India is looking at therapy-aligned acquisition opportunities while seeking to deepen its presence in India's Tier 2 and Tier 3 markets. The company's growth strategy combines potential acquisitions that complement its therapeutic focus with greater penetration beyond India's largest metropolitan markets. The plans signal a broader effort by Novartis India to strengthen its domestic footprint while maintaining alignment with priority therapy areas. Field Content Alert Type Corporate strategy update Company Novartis India Industry Area Pharmaceuticals Geography India Strategic Focus Therapy-aligned acquisitions and expansion into Tier 2 and Tier 3 markets What Happened Novartis India outlined plans to explore acquisition opportunities aligned with its therapeutic priorities while expanding its presence in Tier 2 and Tier 3 markets. Why It Matters The strategy could broaden Novartis India's domestic reach and provide additional growth opportunities while keeping potential acquisitions aligned with the company's existing therapeutic focus. Supporting Context The acquisition plans are prospective rather than a completed transaction, making the development a corporate strategy update rather than a Deals announcement. Key Takeaway Novartis India is pursuing a two-pronged growth strategy centred on therapy-aligned acquisition opportunities and deeper penetration of markets outside India's largest cities. What to Watch Potential acquisition targets and the execution of Novartis India's expansion strategy across Tier 2 and Tier 3 markets. Primary Source Business Standard Relevant Date 6 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- Novartis licenses Alteogen Hybrozyme technology for multiple subcutaneous products
The agreement gives Novartis options to secure exclusive rights to develop and commercialise multiple subcutaneous products using Alteogen's ALT-B4 Hybrozyme technology. Alteogen has entered into an option and licence agreement with Novartis covering the development and commercialisation of subcutaneous formulations of multiple Novartis products using ALT-B4. The deal further expands the global reach of Alteogen's Hybrozyme platform, which uses recombinant human hyaluronidase technology to enable medicines currently administered intravenously to be reformulated for subcutaneous delivery. Field Content Alert Type Deal Companies Alteogen; Novartis Deal Type Option and licence agreement Asset or Company ALT-B4 / Hybrozyme technology Therapy Area(s) Multiple therapeutic areas Technology or Modality Recombinant human hyaluronidase drug-delivery platform Deal Value Financial terms were not disclosed Geography Global What Happened Novartis obtained multiple options to secure exclusive rights to develop and commercialise subcutaneous formulations of multiple products using Alteogen's ALT-B4 Hybrozyme technology. Why It Matters The agreement extends adoption of Alteogen's drug-delivery platform by another major pharmaceutical company and could enable more convenient subcutaneous versions of existing biologic medicines. Supporting Context ALT-B4, or berahyaluronidase alfa, is a recombinant human hyaluronidase designed to facilitate conversion of intravenous biologic medicines into subcutaneous formulations. Strategic Rationale Novartis gains access to a platform that can support more convenient administration of multiple medicines while Alteogen expands the commercial reach of Hybrozyme. Potential Impact Successful development could reduce administration time and improve treatment convenience for products selected under the agreement. Key Takeaway Novartis has secured options to use Alteogen's ALT-B4 platform across multiple subcutaneous product programmes. What to Watch Which Novartis products are selected under the options and subsequent development of ALT-B4-enabled subcutaneous formulations. Primary Source Alteogen Relevant Date 2 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- Cureety acquires Reimagine Care to expand precision oncology platform
The acquisition combines Cureety's therapy-specific oncology monitoring platform with Reimagine Care's AI-enabled virtual cancer-care capabilities. Cureety has acquired US-based Reimagine Care, creating a transatlantic precision-oncology platform supporting more than 250 cancer centres and approximately 100,000 patients across five countries. The combined organisation brings together clinical monitoring and triage technology with AI-supported patient engagement and virtual oncology care, expanding the companies' ability to support patients between hospital visits. Field Content Alert Type Deal Companies Cureety; Reimagine Care Deal Type Acquisition Asset or Company Reimagine Care Therapy Area(s) Oncology Technology or Modality Digital health; AI-enabled virtual oncology care; remote patient monitoring Deal Value Financial terms were not disclosed Geography United States and Europe What Happened Cureety acquired Reimagine Care, combining two digital oncology businesses focused on remote monitoring, patient engagement and virtual cancer care. Why It Matters The transaction creates a larger precision-oncology platform supporting more than 250 cancer centres and around 100,000 patients across five countries. Supporting Context Cureety provides therapy-specific monitoring and clinical triage technology, while Reimagine Care provides AI-supported patient engagement and virtual oncology services. Strategic Rationale The acquisition combines complementary technology and care-delivery capabilities to support more continuous cancer care outside traditional clinical settings. Potential Impact The enlarged platform could help oncology providers monitor more patients remotely, identify deterioration earlier and reduce administrative burden on care teams. Key Takeaway Cureety's acquisition of Reimagine Care creates a scaled transatlantic digital oncology organisation serving more than 100,000 patients. What to Watch Integration of Reimagine Care's AI and virtual-care capabilities into Cureety's platform and expansion across additional oncology providers. Primary Source Cureety Relevant Date 2 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- GSK licenses HUTCHMED cancer therapy HMPL-A830 in deal worth up to $1.295bn
The agreement gives GSK worldwide rights outside Greater China to develop and commercialise HUTCHMED's first-in-class KRAS-EGFR antibody-targeted therapy conjugate HMPL-A830. HUTCHMED will receive $110 million upfront and is eligible for a further $1.185 billion in development, regulatory and commercial milestones, taking the potential deal value to $1.295 billion, plus tiered royalties. HMPL-A830 is expected to enter clinical development in the second half of 2026, initially targeting colorectal, pancreatic and lung cancers with KRAS alterations. Field Content Alert Type Deal Companies GSK; HUTCHMED Deal Type Exclusive development and licence agreement Asset or Company HMPL-A830 Therapy Area(s) Oncology; colorectal cancer; pancreatic cancer; lung cancer Technology or Modality KRAS-EGFR antibody-targeted therapy conjugate Deal Value Up to $1.295 billion, including $110 million upfront and up to $1.185 billion in development, regulatory and commercial milestone payments, plus tiered royalties Development Stage Preclinical / preparing for Phase I clinical development Geography Worldwide rights excluding Mainland China, Hong Kong, Macau and Taiwan What Happened GSK secured exclusive development and commercialisation rights outside Greater China to HUTCHMED's HMPL-A830, a first-in-class KRAS-EGFR antibody-targeted therapy conjugate. Why It Matters The transaction gives GSK access to a novel precision-oncology platform designed to deliver a KRAS inhibitor directly to EGFR-expressing tumours while simultaneously blocking EGFR and KRAS signalling. Supporting Context HUTCHMED expects global Phase I development of HMPL-A830 to begin in the second half of 2026, initially focusing on colorectal, pancreatic and lung cancers. Strategic Rationale GSK gains a differentiated KRAS-targeted oncology candidate while HUTCHMED retains development and commercialisation rights in Greater China. Potential Impact If successful, HMPL-A830 could provide a new targeted approach for patients with KRAS-altered tumours that remain difficult to treat with existing therapies. Key Takeaway GSK is committing up to $1.295 billion for ex-Greater China rights to HUTCHMED's novel KRAS-EGFR oncology candidate HMPL-A830. What to Watch Initiation of the global Phase I programme and early clinical evidence for HMPL-A830 in KRAS-altered solid tumours. Primary Source HUTCHMED Relevant Date 3 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- FDA approves Zanvastro as first treatment for Alexander disease
The FDA has approved Zanvastro as the first treatment for Alexander disease in paediatric and adult patients. Zanvastro, also known as zilganersen, is the first FDA-approved therapy for Alexander disease and the first treatment designed to directly address the GFAP protein accumulation that drives the rare neurological disorder. The approval introduces a disease-targeted treatment for patients who previously had no approved therapeutic option beyond supportive care. Field Content Alert Type Approval Drug Name Zilganersen Brand Name Zanvastro Company Ionis Pharmaceuticals Regulatory Authority U.S. Food and Drug Administration Approval Type New drug approval Indication Treatment of Alexander disease in paediatric and adult patients Therapy Area(s) Neurology; rare disease Geography United States What Happened The FDA approved Zanvastro (zilganersen) for the treatment of Alexander disease in paediatric and adult patients. Why It Matters Zanvastro is the first FDA-approved treatment for Alexander disease and the first therapy designed to directly target the underlying protein accumulation driving the disorder. Supporting Context Alexander disease is a rare progressive neurological disorder caused by mutations affecting glial fibrillary acidic protein, or GFAP. Key Takeaway FDA approval of Zanvastro establishes the first disease-targeted treatment option for people with Alexander disease. What to Watch Clinical adoption of Zanvastro and longer-term evidence on its impact across paediatric and adult Alexander disease populations. Primary Source U.S. Food and Drug Administration Relevant Date 3 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- Cipla licenses Qilu's Keytruda biosimilar for the US
The agreement gives Cipla exclusive US commercialisation rights to Qilu Pharmaceutical's pembrolizumab biosimilar candidate QL2107, referencing Keytruda. Cipla subsidiary Invagen Pharmaceuticals has entered into an exclusive licensing and supply partnership with Qilu, which will remain responsible for development, regulatory registration and product supply. Cipla USA will commercialise the biosimilar in the United States, positioning the company to participate in the future US market for biosimilar versions of Merck's blockbuster cancer immunotherapy Keytruda. Field Content Alert Type Deal Companies Cipla; Invagen Pharmaceuticals; Qilu Pharmaceutical Deal Type Exclusive licensing and supply partnership Asset or Company QL2107 Therapy Area(s) Oncology Technology or Modality Pembrolizumab biosimilar; PD-1 monoclonal antibody Deal Value Financial terms were not disclosed Geography United States What Happened Cipla subsidiary Invagen Pharmaceuticals entered into an exclusive partnership with Qilu Pharmaceutical for the licensing and supply of QL2107, a biosimilar referencing Keytruda, in the United States. Why It Matters The partnership gives Cipla access to a potential US biosimilar of one of the world's leading oncology medicines and expands its biologics commercialisation portfolio. Supporting Context Qilu will remain responsible for development, regulatory registration and supply, while Cipla USA will handle commercialisation in the US. Strategic Rationale The deal combines Qilu's biosimilar development capabilities with Cipla's established US commercial infrastructure. Potential Impact A successfully approved pembrolizumab biosimilar could increase competition and broaden access to PD-1 immunotherapy in the US oncology market. Key Takeaway Cipla has secured exclusive US commercialisation rights to Qilu's Keytruda biosimilar candidate QL2107. What to Watch US regulatory development of QL2107 and the timing of potential entry into the pembrolizumab biosimilar market. Primary Source Cipla Relevant Date 3 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- Samsung Bioepis gains Japanese approval for intravenous Stelara biosimilar
Samsung Bioepis has received Japanese marketing approval for a 130mg intravenous formulation of its ustekinumab biosimilar referencing Stelara. The newly approved intravenous formulation is indicated as induction therapy for patients with moderate-to-severe active Crohn's disease where other treatments are ineffective. The approval is Samsung Bioepis' second Japanese ustekinumab biosimilar approval through its partnership with NIPRO, following the previously approved 45mg subcutaneous syringe formulation. Field Content Alert Type Approval Drug Name Ustekinumab biosimilar Brand Name Ustekinumab BS Intravenous Infusion 130mg NIPRO Company Samsung Bioepis; NIPRO Corporation Reference Product Stelara Regulatory Authority Japanese regulatory authorities Approval Type Marketing approval Indication Induction therapy for moderate-to-severe active Crohn's disease where other treatments are ineffective Therapy Area(s) Gastroenterology; inflammatory bowel disease Geography Japan What Happened Samsung Bioepis received Japanese marketing approval for the 130mg intravenous formulation of its ustekinumab biosimilar referencing Stelara. Why It Matters The approval expands the available formulations of Samsung Bioepis' ustekinumab biosimilar in Japan and provides an intravenous induction option for eligible Crohn's disease patients. Supporting Context The approval follows the earlier Japanese approval of the 45mg subcutaneous syringe formulation through Samsung Bioepis' partnership with NIPRO Corporation. Key Takeaway Samsung Bioepis has expanded its Japanese ustekinumab biosimilar offering with approval of a 130mg intravenous induction formulation. What to Watch Commercial rollout through NIPRO and adoption of the intravenous biosimilar in Japanese Crohn's disease treatment. Primary Source Samsung Bioepis Relevant Date 3 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- US Pulmonologist Compensation Reaches $441,472 in Doximity’s 2026 Report
Average annual compensation for US pulmonologists reached $441,472 in Doximity’s 2026 Physician Compensation Report, providing an updated national benchmark for physicians working in pulmonology. US pulmonologists recorded average annual compensation of $441,472, according to Doximity’s 2026 Physician Compensation Report. The latest figure provides pulmonologists with a specialty-specific benchmark when evaluating their compensation, employment opportunities and the financial expectations associated with their practice. Key findings Doximity reports average annual compensation of $441,472 for pulmonologists in its 2026 Physician Compensation Report. For pulmonologists, the figure provides a useful national reference point within a specialty focused on the diagnosis, treatment and long-term management of respiratory disease. The national average should not be interpreted as the compensation every pulmonologist will receive. Individual earnings can vary according to geography, experience, patient volume, disease focus, procedural activity, call responsibilities, practice setting and employment structure. Pulmonologist compensation reaches $441,472 The $441,472 average establishes a current national compensation benchmark for US pulmonologists. Pulmonology encompasses the management of a broad range of respiratory conditions, including asthma, chronic obstructive pulmonary disease (COPD), interstitial lung disease, pulmonary hypertension, sleep-related breathing disorders and other acute and chronic pulmonary conditions. Clinical practice can combine outpatient consultations and long-term disease management with inpatient respiratory care and diagnostic procedures such as bronchoscopy and pulmonary function assessment. Individual pulmonologists may also develop expertise in areas such as interventional pulmonology, pulmonary hypertension, interstitial lung disease, lung transplantation or sleep medicine, creating considerable variation between individual practices. For pulmonologists reviewing their current compensation or considering a new position, the Doximity figure provides a useful specialty-specific reference against which an individual package can be assessed. What influences pulmonologist compensation? Pulmonology combines longitudinal patient management with diagnostic and procedural activity, meaning patient volume, disease complexity, procedural workload and subspecialty focus can all be important when evaluating individual compensation. A pulmonologist managing complex interstitial lung disease or pulmonary hypertension may have a different clinical workload from a physician whose practice includes a greater proportion of general respiratory medicine or procedural pulmonology. Hospital and call responsibilities can also affect the demands of individual roles, particularly where pulmonologists provide inpatient respiratory consultations or participate in acute respiratory care. Geography, experience and employment model can further influence compensation. Pulmonologists may work within hospitals, health systems, academic medical centres, specialist pulmonary groups or other practice structures, with different organisations using different salary, productivity and incentive arrangements. These factors mean the $441,472 national average should be treated as a benchmark rather than an expected salary for every pulmonologist. What the latest figure means for pulmonologists For US pulmonologists, $441,472 provides a contemporary national reference point when benchmarking existing compensation or assessing a prospective position. When reviewing an employment opportunity, pulmonologists should consider headline compensation alongside expected patient volumes, disease complexity, procedural responsibilities, call commitments, working hours and productivity requirements. The precise clinical focus of the role is particularly important. The workload associated with interventional pulmonology, pulmonary hypertension or advanced lung disease can differ substantially from that of a predominantly outpatient general pulmonology practice. The latest Doximity figure therefore provides pulmonologists with a useful starting point for evaluating compensation while recognising that individual earnings can differ substantially according to the clinical and contractual characteristics of a particular role. About the data The Doximity 2026 Physician Compensation Report provides compensation benchmarks across a wide range of US medical and surgical specialties. The specialty figures represent average compensation and should be treated as national benchmarks. An individual pulmonologist’s compensation may differ according to geography, experience, patient volume, disease focus, procedural activity, call responsibilities, practice setting and other professional factors. Source Doximity. Physician Compensation Report 2026.https://www.doximity.com/reports/physician-compensation-report/2026#modal-close Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com



